Olurotimi O. Mesubi

This study shows SGLT2 inhibitors reduce diabetic cardiomyopathy and atrial fibrillation risk in T2D mice, but their effects are not dependent on CaMKII inhibition.

The paper develops a CaMKII biosensor for high-throughput screening and identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor effective in preventing atrial fibrillation.

This paper shows that excessive O-GlcNAcylation causes heart failure and sudden death in mice, while reducing it protects against cardiac stress.

This study shows that O-GlcNAcylation and oxidative stress via CaMKII contribute to atrial fibrillation in type 1 and type 2 diabetes through distinct mechanisms.